Dolutegravir suppresses HIV in pregnant women without upping neural tube defect risk
10 Aug 2020
bởiJairia Dela Cruz
The benefit of using dolutegravir for HIV treatment in pregnant women outweighs the risk. This is the message delivered by two studies presented at the 23rd International AIDS Conference, which have shown that the drug induces rapid viral suppression and brings a slight but nonsignificant risk of neural tube defects (NTDs) compared with other antiretrovirals.
